849221-94-9: Cabozantinib Desfluoro Impurity
It is one of impurity present in Cabozantinib, Cabozantinib is a tyrosine kinase inhibitor, which inhibits the activity of c-MET vascular endothelial growth factor receptor and other tyrosine kinases, thereby leading to reduced tumor angiogenesis motility and invasiveness. which is used in the treatment of progressive, metastatic medullary thyroid cancer, also indicated for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma.
Additional information on CAS 849221-94-9
VE007673
849221-94-9
C28H25N3O5
483.52 g/mol
Cabozantinib
N-(4-(6, 7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(phenyl)-cyclopropane-1, 1-dicarboxamide
N/A
Osanto, S., & van der Hulle, T. (2018). Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Therapeutic Advances in Urology, 10(3), 109–123. https://doi.org/10.1177/1756287217748867
In-stock
